Head to Head Contrast: Evofem Biosciences (NASDAQ:EVFM) and Kyntra Bio (NASDAQ:KYNB)

Evofem Biosciences (NASDAQ:EVFM) and Kyntra Bio (NASDAQ:KYNB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Institutional & Insider Ownership

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 2.0% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for Evofem Biosciences and Kyntra Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0	0	0	0	0.00
Kyntra Bio	1	1	0	1	2.33

Profitability

This table compares Evofem Biosciences and Kyntra Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
Kyntra Bio	2,199.13%	N/A	-36.71%

Volatility & Risk

Evofem Biosciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.

Valuation and Earnings

This table compares Evofem Biosciences and Kyntra Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39 million	0.08	$52.98 million	($0.07)	-0.10
Kyntra Bio	$6.44 million	4.34	$183.45 million	$40.46	0.17

Kyntra Bio has lower revenue, but higher earnings than Evofem Biosciences. Evofem Biosciences is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Kyntra Bio beats Evofem Biosciences on 12 of the 13 factors compared between the two stocks.

About Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.